देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
Triclabendazole
Bimeda Animal Health Limited
QP52AC01
Triclabendazole
10 percent weight/volume
Oral suspension
POM: Prescription Only Medicine as defined in relevant national legislation
triclabendazole
Authorised
2002-02-22
Health Products Regulatory Authority 03 May 2019 CRN008M6G Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Fasifree 10% w/v Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE Triclabendazole 100 mg EXCIPIENTS Methyl Parahydroxybenzoate (E218) Ph.Eur. 2.0 mg (preservative) Propyl Parahydroxybenzoate (E216) Ph.Eur. 0.2 mg (preservative) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension. A white to off-white oral suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle and Sheep. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment and control of adult, immature and early immature stages of liver fluke (_Fasciola hepatica) _susceptible to triclabendazole. 4.3 CONTRAINDICATIONS Do not use in animals known to be hypersensitive to the active substance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device. Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Resistance to triclabendazolehas been reported in _Fasciola hepatica _in cattle and sheep.Therefore, the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of the _Fasciola hepatica _and recommendations on how to limit further selection for resistance to पूरा दस्तावेज़ पढ़ें